Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
RBN Altcoin..upgraded to $5 prepandemic! TONIGHT!!!
Watch the MOASSSSSSSSS and FOMO!!!
COVAL altcoin... TO Explode to $1.25 underway on latest EM projection comparisons to DOGE.
PER EM COVAL TO RUN TO $1.25 Near term!
WE RICH!!! RETIRE EARLY!!
Hidden Truths - #israel
Cphi $.32 -1 Mill float news watch medical device launch first half of 2024
News from —> 11/29/23
QUOTE
“”We are actively working to try to launch this product in the first half of next year. We are confident that with the patented technological advantages and our sales channels, the launch of this product will bring excellent treatment experience to every DED patient, which will create value for our shareholders."”
after split 1-for 5 (3/6/24)
1 Million float
10 Mill o/s
Insiders own 86% per finviz*
Chart -> https://schrts.co/EjjTrTmK
Finviz -> https://finviz.com/quote.ashx?t=CPHI&p=d
News —> 11/29/23
China Pharma Holdings, Inc. Announced the Completion of Third Party Testing of Dry Eye Disease Therapeutic Device
Source: PR Newswire (US)
HAIKOU, China, Nov. 29, 2023 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma", or the "Company"), an NYSE American-listed corporation with a fully-integrated specialty pharmaceuticals subsidiary based in China, today announced that its Dry Eye Disease (DED) therapeutic device has passed third-party testing and is preparing to apply for market launch to the National Medical Products Administration (NMPA) of China.
According to a disclosure by the Shanghai Public Health Clinical Center on June 6, 2023, an epidemiological survey of DED showed that approximately 344 million patients are suffering from DED worldwide, accounting for 30% of the total number of ophthalmic outpatient visits, with an annual increase of 10%. There are about 80 million DED patients in China, ranking second in ophthalmic diseases.
This device has a utility model patent;
Epidemiological research shows that the incidence rate of DED for all the people in China is about 25% to 30%, and about 75% for people over 65-year-old;
In the field of DED and visual fatigue, this product is expected to fill in the market gap of medical therapeutic apparatus; and
The Company has established sales channels in more than 30 provincial and municipal hospitals, as well as OTC markets in China for more than 20 years. This sales network may strongly support the launch and promotion of this device.
Ms. Li Zhilin, CEO of China Pharma said: " After passing third-party testing, this product has obtained qualifications to apply for market approval from NMPA. We are actively working to try to launch this product in the first half of next year. We are confident that with the patented technological advantages and our sales channels, the launch of this product will bring excellent treatment experience to every DED patient, which will create value for our shareholders."
About China Pharma Holdings, Inc.
China Pharma Holdings, Inc. is a specialty pharmaceutical company that develops, manufactures and markets a diversified portfolio of products, focusing on conditions with high incidence and high mortality rates in China, including cardiovascular, CNS, infectious, and digestive diseases. The Company's cost-effective business model is driven by market demand and supported by new GMP-certified product lines covering the major dosage forms. In addition, the Company has a broad and expanding nationwide distribution network across all major cities and provinces in China. The Company's wholly-owned subsidiary, Hainan Helpson Medical & Biotechnology Co., Ltd., is located in Haikou City, Hainan Province. For more information about China Pharma Holdings, Inc., please visit www.chinapharmaholdings.com. The Company routinely posts important information on its website.
Safe Harbor Statement
Certain statements in this press release constitute forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Any statements set forth above that are not historical facts are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties may include, but are not limited to: the achievability of financial guidance; success of new product development; unanticipated changes in product demand; increased competition; downturns in the Chinese economy; uncompetitive levels of research and development; and other information detailed from time to time in the Company's filings and future filings with the United States Securities and Exchange Commission. The forward-looking statements made herein speak only as of the date of this press release and the Company undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the Company's expectations, except as required by applicable law or regulation.
Cision View original content:https://www.prnewswire.com/news-releases/china-pharma-holdings-inc-announced-the-completion-of--third-party-testing-of-dry-eye-disease-therapeutic-device-302000153.html
SOURCE China Pharma Holdings, Inc.
Copyright 2023 PR Newswire
EZGO...............TUP...................................https://stockcharts.com/h-sc/ui?s=EZGP&p=W&yr=1&mn=3&dy=0&id=p96837884856
https://stockcharts.com/h-sc/ui?s=TUP&p=W&yr=1&mn=3&dy=0&id=p96837884856
$EARI onward and upward $$
BSGM
$BSGM doesnt get any better than this pic.twitter.com/pQz268hsVb
— i_like_bb_stock (@thommic) May 3, 2024
COVAL altcoin !!Correct back to $1 in a few minutes..prepandemic! We win! Enjoy the FOMO!
$SINT Power Hour Here next week .10 coming get your cheap shares today
$AGBA $3.35 +7.37% 5-day change +39.29% YTD +542.64%
@nasdaq quote https://marketscreener.com/quote/stock/AGBA-GROUP-HOLDING-LIMITE-146900535/
$CBIA Mystery Acquisition
https://www.youtube.com/shorts/sENklnghApw
ilst grabbed some .0021's from friday sellers
$IGPK :JFHE
— TheStockGuru (@Austria_9999) May 3, 2024
Time to BUY now.
Anything can happen anytime now.
1:00 pm now only 2 hrs left to reach 3:00pm
After that buy will be on Monday.
SPZI $$$ PARABOLIC MOVE COULD BE IMMINENT, MULTI-DOLLARS MONSTER IN THE MAKING !!!
$LVVV Livewire Ergogenics’ Estrella River Farms Passes 14th Compliance Inspection
ERF Holds one of Forty Large Outdoor Cultivation Licenses in California
https://stockwatchindex.com/livewire-ergogenics-estrella-river-farms-passes-14th-compliance-inspection-erf-holds-one-of-forty-large-outdoor-cultivation-licenses-in-california/
BLEG.
Dave Oswald
@Dave_Oswald_CEO
·
4m
Exactly. We will pr any major/material event as they happen… Look for some pretty big announcements in the next week or two $BLEG
CETX closed offering and facial recognition tech now can detect firearms
BLEG new tweet out!! Lab ready
Power is on at $BLEG! LFG!!! pic.twitter.com/e4zTfz35xA
— Dave Oswald (@Dave_Oswald_CEO) May 3, 2024
$RENB $1.50 HOD $1.58 RENOVARO IS TRANSFORMING CANCER DETECTION: RENOVAROCUBE INTRODUCES FLAMINGO, A NOVEL #AI MODEL BASED ON FRAGMENTOMICS https://renovarobio.com/news/transforming-cancer-detection-renovarocube-introduces-flamingo-a-novel-ai-model-based-on-fragmentomics/ $TWST
$KULR on Twitter: "Don't miss our CEO's interview
Discover how KULR is driving triple-digit growth and pioneering energy solutions for space and military applications."
Watch the full interview here:
Don't miss our CEO's interview with @smallcapvoice Discover how KULR is driving triple-digit growth and pioneering energy solutions for space and military applications.
— KULR Technology (@KULRTech) May 3, 2024
Watch the full interview here: https://t.co/ysSMX3kQ4H#KULRTechnology #Innovation $KULR
MWRK is picking up the last week. Has it bottomed?
$BANT "note's conversion feature was removed" game changer imo. https://finance.yahoo.com/news/bantec-restated-senior-secured-note-140000380.html
$AKAN strong oversold / weed - crypto stock
$EARI 000 weed plays can be as fruitful as the recent 000 crypto theme was recently.
$KULR and Amprius: Revolutionizing Battery Technology
MULN...............................................https://stockcharts.com/h-sc/ui?s=MULN&p=W&yr=1&mn=3&dy=0&id=p96837884856
$JAGX 🔥🔥🔥🔥 just starting to move to new and higher levels and new highs 🚀🚀🚀
imo
$JAGX is about to go back up WOW BOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOM
$AGBA on http://Seekingalpha.com @agbagroup says @Triller merger 'elevating shareholder value to new heights' https://seekingalpha.com/news/4091483-agba-group-says-triller-merger-elevating-shareholder-value-to-new-heights?source=tweet
$AMPH $HZMP $VRTX $IRON $ACAD $GILD $LLY $AMEG
Updates $BLEG
Ending the week strong at $BLEG! 🏋️♂️
— Dave Oswald (@Dave_Oswald_CEO) May 3, 2024
*Final product samples given to 2 new white label clients 🫙
*Preparing grant submissions for clinical trials 📑
*Negotiations underway to be the sole supplier of kratom alkaloids for clinical applications 💉💊
AZTR .22 news catalyst next week : The data will be presented on Friday, May 10, 2024
We are thrilled to announce new preclinical data for our precision dermatology platform that demonstrate proof-of-concept data supporting the use of genetically engineered skin commensals to deliver proteins to the skin,” said Travis Whitfill, Azitra’s co-founder and COO. “These data show the robust preclinical activity of ATR-12 in Netherton syndrome models and further supports the rationale behind our Phase 1b clinical trial in Netherton syndrome patients.”
ZAPP took a few here in case they go for it again post split with BENF MI AWIN moving
$EPAZ https://seekingalpha.com/news/4086285-epazzs-unit-files-second-patent-for-solid-state-battery-technology-for-drones-electric-airplanes @epazz #galaxybatteries #highvoltage #drones
$AGBA -Building a Digital Economy Titan: AGBA and Triller Combine in $4 Billion Merger
$TLRY breakout incoming - marijuana
$TLRY hourly chart
— Ludlow Research (@LudlowResearch) May 3, 2024
$2.20 could be #FOMO breakout trigger $CGC $ACB $CRON $WEED $SPY $AMC $TSLA #marijuana #cannabis pic.twitter.com/850v0CrKRJ
ONVO: 1.17+0.2196 (+23.1103%)
Organovo Holdings (NASDAQ:ONVO) is a biotechnology company that is both a developer of 3D tissue technology that has the potential to change the way treatments are discovered and tested, as well as being a creator of new therapies using that technology.
The company recently released Phase 2 results for one of the therapies being advanced by ONVO by the name of FXR 314. The trial was to determine the effectiveness of FXR314 in treating metabolic function-associated steatohepatitis (MASH), which is a condition affecting approximately 115 million people worldwide according to the Boehringer Institute, which is expected to increase by roughly 25% by 2050. MASH, briefly, is a condition that can develop when excess fat is stored in the liver and causes inflammation of the liver, which can lead to a variety of problems, including liver failure. The serious nature of this condition is part of the reason we are excited about results from the Phase 2 trial, which showed a significant reduction in liver fat content for trial participants, with a mean reduction of 23% for those with 3 mg doses of FXR314, compared to a 6.1% reduction seen in those participants with a placebo.
Additionally, the company found that FXR 314 was found to be safe and effective. CEO Keith Murphy noted that, “The key findings of this study are that the once daily oral FXR314 demonstrated statistically significant liver fat reduction and excellent tolerability.”
These results reinforce our belief that ONVO is pursuing a path for developing drugs that is more effective and efficient and should prove to produce more impactful treatments.
As mentioned above, the company is a developer of 3D technology as well as a creator of new therapies. It is this dual path and how the two paths can work together that continues to excite us about Organovo. Regarding the 3D technology, Organovo’s advances in the area include cell type-specific compartments, prevalent intercellular tight junctions, and the formation of microvascular structures. Management believes these attributes can enable critical complex, multicellular disease models that can be used to develop clinically effective drugs across multiple therapeutic areas. The company’s technology, known as NovoGen Bioprinters, are automated devices that enable the fabrication of 3D living tissues comprised of mammalian cells. The Company believes that the use of its bioprinting platform as well as complementary 3D technologies will allow it to develop an understanding of disease biology that leads to validated novel drug targets and therapeutics to those targets to treat disease. To this point, the company’s technology has been used to create a wide variety of tissues such as: healthy liver, NASH (nonalcoholic steatohepatitis) liver, kidney, intestine, skin, vascular, bone, skeletal muscle, eye, breast and pancreatic tumor.
There are two avenues that we believe the company can benefit from this technology. First, Organovo can use the technology internally to develop drugs that are able to be tailored more specifically to the targeted condition because the company can manipulate the 3D created tissues to reflect the disease as it would appear in actual human tissue. This also allows the company to move through the initial stages of research and testing in a more rapid and precise manner, which makes the process more efficient and cost effective and the treatments potentially more effective.
Additionally, many clinical stage companies have no revenue inflows to help offset the costs of developing much needed treatments. However, as already demonstrated, Organovo has the ability to license the company’s 3D technology to other companies to aid in their research process, leading to a revenue stream coming into Organovo as it continues to push to bring treatments to the market. According to company management, any deal achieved with a pharma company, Organovo intends to avoid “fee for services” revenue, which it believes provides limited benefit. Instead, the company will target deals with large, up-front payments, followed by milestone payments that the company believe could be in the hundreds of millions of dollars. These deals will involve the company working with the pharma partner to push novel drugs to the market. The partner company would own the rights to the drug, but Organovo would expect to earn milestone payments as a drug advances and royalties upon a drug’s commencement of commercial sales. These deals can be hard to predict the timing or probability of, but when achieved they have the potential to provide further validation of the company’s science and approach, as well as being a potential catalyst for investors.
We believe Organovo is at a good spot for potential investors, with positive test results providing confidence that the company is on the right track.
STRH interesting
$strh interesting move over last few days and large bidder pic.twitter.com/kIQAhrCtHE
— i_like_bb_stock (@thommic) May 3, 2024
💲🛫$EARI 000 weed plays can be as fruitful as the recent 000 crypto theme was recently.
Followers
|
9993
|
Posters
|
|
Posts (Today)
|
119
|
Posts (Total)
|
4967305
|
Created
|
01/10/04
|
Type
|
Free
|
Moderator i_like_bb_stock | |||
Assistants koolmc MOMO vantillian Rainer StockRocket |
Goal: TO PROVIDE A FORUM FOR BOTH EXPERIENCED AND NOVICE TRADERS TO SHARE THEIR OPINIONS ON STOCKS TRADED ON THE BULLETIN BOARD OR PINK SHEET MARKETS, AS WELL AS THE BIG BOARDS. FUNDAMENTALS, NEWS, RUMORS ARE WELCOME, BUT FOR THE MOST PART, THIS BOARD WILL BE TO SHARE TECHNICAL ANALYSIS. TIMING IS EVERYTHING WHEN BUYING OR SELLING A STOCK, AND TECHNICAL ANALYSIS CAN OFTEN DETERMINE THE APPROPRIATE ACTION TO TAKE. ALL TECHNICAL INDICATORS ARE WELCOME. FOR NOVICE TRADERS, QUESTIONS ARE WELCOMED, AND SOMEONE WILL TRY AND HELP YOU WITH THE ANSWER. I WAS ONCE A NOVICE TRADER, AND KNOW THAT GUIDANCE WOULD HAVE HELPED ME SEVERAL YEARS AGO, SO I WOULD LIKE TO HELP YOU AS MUCH AS POSSIBLE. -- i_like_bb_stock |
Rules:1) Spam of any kind will not be tolerated2) There will be times when posters are not in agreement, that is healthy, but please no personal attacks. 3) No specific price preference for the board but these are mostly OTC stocks. 4) Volume is the blood in a stock's veins, so I typically prefer stocks with historical volume, otherwise there is little liquidity for selling the stock if need be. 5) Posting charts and annotations if you have a service that provides it are highly welcome since this provides support for your buy/sell/hold signal. 6) As always, do your due diligence, and remember that there is high risk in these types of stocks. Never trade with money that you cannot afford to loose. 7) If the post is Off Topic, please post with OT prefacing the post. |
Some relevent info:1) For SEC filings I use www.otcmarkets.com.2) For daily charts I use www.stockcharts.com. There is a free service which is time delayed, and then different levels of paid service. 3) To post a chart from stockcharts.com, right click on the chart, click "Copy Image URL". Within the post, right click and click Paste. Remove "http://" then place the chart URL between these tags [*chart]URL[*/chart] (remove the asterisks) 4) For level II, there are various services, IHUB has its own services, individual brokers as well, I use TDAmeritrade, which offers free level II if you have an account. 5) I use equityfeed.com which is critical for any otc trader. It has level II as well, real time news, scanning, and a plethora of things that are needed as a trader. There are various price points based on your needs. 6) For a great listing of stock terms or investor information, use www.investopedia.com or www.investorwords.com. 7) For more info on chart formations, see http://www.chartpatterns.com and http://thepatternsite.com. 8) To find splits, symbol changes etc., use http://otce.finra.org/DailyList 9) Remember also to sell into strength and buy into weakness. When possible, try not to sell at the bid. When a stock is strong, you can usually at least get filled somewhere between the bid/ask, selling at the bid will often hurt the stock, since the market makers make take the bid down further afterwards. 10) For info on stockcharts.com, see the Stockcharts board on the Hub: http://www.investorshub.com/boards/board.asp?board_id=1277 |
Posts Today
|
119
|
Posts (Total)
|
4967305
|
Posters
|
|
Moderator
|
|
Assistants
|
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |